Fredric Finkelstein, MD
Nephrology · New Haven, CTNPI 1851387088
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $49,259 of the $70,214 with a category attached, or 70.2%. GSK accounts for 64.9% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $26,090 and has fallen 99.8% since, to $56 in 2025. Among nephrology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 358 payments — averaging $196.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$46K
- AstraZeneca$12K
- Travere Therapeutics, Inc.$5K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
- Amgen$1K
- Vifor Pharma, Inc.$884
- plus $3K from 26 others
Across 4 payments — averaging $16,517 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Fresenius USA Marketing, Inc.$66K
- Akebia Therapeutics Inc$68
What the payments were for
- Consulting fees$49,25970%
- Speaking & faculty fees$2490%
- Travel & lodging$13,05419%
- Food & beverage$7,43511%
- Education$2170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 39 | $45,575 |
| AstraZeneca(2 entities) | 68 | $12,213 |
| Travere Therapeutics, Inc. | 26 | $4,854 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $2,295 |
| Amgen(2 entities) | 45 | $1,074 |
| Vifor Pharma, Inc. | 34 | $884 |
| Fresenius USA Marketing, Inc. | 13 | $457 |
| Akebia Therapeutics Inc | 16 | $362 |
| Otsuka America Pharmaceutical, Inc. | 13 | $293 |
| Mallinckrodt Hospital Products Inc. | 10 | $268 |
| Aurinia Pharma U.S., Inc. | 12 | $253 |
| Novo Nordisk | 9 | $201 |
| Sanofi | 8 | $185 |
| Calliditas Therapeutics US Inc. | 6 | $137 |
| Ardelyx, Inc. | 6 | $136 |
| Xeris Pharmaceuticals, Inc. | 7 | $130 |
| Boehringer Ingelheim | 5 | $111 |
| Bayer | 5 | $110 |
| Novartis | 6 | $107 |
| Genentech USA, Inc. | 6 | $85 |
| Ultragenyx Pharmaceutical Inc. | 4 | $78 |
| Alnylam Pharmaceuticals Inc. | 3 | $76 |
| Baxter Healthcare | 1 | $61 |
| Lilly USA, LLC | 2 | $54 |
| ANI Pharmaceuticals, Inc. | 2 | $52 |
| Kyowa Kirin, Inc. | 2 | $44 |
| OPKO Pharmaceuticals, LLC | 2 | $41 |
| Cormedix Inc. | 1 | $18 |
| Bard Peripheral Vascular, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$70,214 in reported general payments places this provider in the 95th percentile of 144 nephrology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 58 | $47,917 |
| JardianceEmpagliflozin | 23 | $16,907 |
| Sevelamer Carbonate | 23 | $4,635 |
| Lisinopril | 28 | $499 |
| Allopurinol | 44 | $411 |
| Furosemide | 48 | $393 |
| Metoprolol Succinate | 26 | $198 |
| Losartan Potassium | 31 | $197 |
| Amlodipine Besylate | 46 | $143 |
| Hydrochlorothiazide | 24 | $123 |
| Spironolactone | 18 | $119 |
| Rosuvastatin Calcium | 13 | $105 |
| Pantoprazole Sodium | 14 | $87 |
| Atorvastatin Calcium | 13 | $50 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $12,213 | $47,91758 claims |
| Boehringer IngelheimJardiance | $111 | $16,90723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 144 nephrology providers in Connecticut.
Other nephrology in New Haven
- Robert AlpernNew Haven$4.9M
- Richard FormicaNew Haven$198K
- Stefan SomloNew Haven$111K
- Justin BelcherNew Haven$59K
- Ladan GolestanehNew Haven$54K
- Aldo PeixotoNew Haven$17K
- Ali Abu-AlfaNew Haven$16K
- Lloyd CantleyNew Haven$14K
- Sue ChangNew Haven$9K
- Margaret BiaNew Haven$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.